Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

several weeks following

treatment.

Additional Development

-- Anesiva out-licensed worldwide rights to its NF-kappa B Decoy program

to Transcription Factor Therapeutics, Inc. Anesiva will receive an

upfront licensing fee, and will be entitled to receive milestone

payments totaling up to $114 million if two products are

commercialized. NF-kappa B is a protein implicated in autoimmune and

inflammatory disease processes, therapeutic areas outside Anesiva's

current focus on pain management.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit http://www.zingo.com. An sNDA is under review at FDA to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in Phase 3 clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown to reduce pain after only a single administration for up to weeks to months in multiple settings based on the results of several mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
(Date:8/28/2014)... 2014 Earlier this month, a ... partnership with the U.S. Air Force on the performance ... indicated that this type of fuel made from mustard ... be important to America’s Eco friendly future. In fact, ... mandate to become independent of foreign oil over the ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... Software Inc., the leading,provider of web-based employee ... independent research firm Bersin & Associates ranked,Halogen ... its recent report on talent,management vendors. Halogen ... product strength, architecture and customer satisfaction., ...
... BioSeek, Inc. today,announced that Roy A. Whitfield ... of directors. Mr. Whitfield had joined BioSeek,s board ... the Company since November,2005., "Roy,s management experience ... been extraordinarily valuable to BioSeek thus,far. We look ...
... - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY), a biotechnology ... for the treatment of cancer, today,announced the launch ... ., "We are excited about our new ... which provides additional information about our,product pipeline and ...
Cached Biology Technology:Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction 2BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors 2
(Date:8/31/2014)... is available in French . ... just published in the prestigious Nature Neuroscience journal ... Centre of the Douglas Mental Health University Institute and McGill ... circuitry and dynamic mechanisms controlling memory as well of the ... sub-region named the subiculum. , In 2009, they developed ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
... map data into BiblioSphere , Genomatix Software GmbH ... Science (AAAS) today announced an agreement that allows ... Environment into Genomatix's BibliospherePE pathway knowledge base and ... journal Science, developed the Signal Transduction Knowledge Environment, ...
... of a protein, human CD38, which may lead to important ... in almost every cellular process. The findings also may offer ... to diabetes and HIV-AIDS. , Levels of the ... human CD38 a marker for these diseases. , As ...
... at the National Institute of Child Health and Human ... parasite disperses from the red blood cells it infects. ... Development is one of the Institutes comprising the National ... September 20 Current Biology. , "This discovery provides the ...
Cached Biology News:Genomatix, AAAS ink agreement 2Protein structure key for AIDS, cell function 2Researchers discover how malaria parasite disperses from red blood cells 2Researchers discover how malaria parasite disperses from red blood cells 3
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: